Indigenously developed COVID-19 vaccine, Covaxin, neutralises multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well, the Indian Council of Medical Research (ICMR) said on Wednesday.
Bharat Biotech’s Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the globe with another 60 in the process.
ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well. @MoHFW_INDIA @DeptHealthRes #IndiaFightsCOVID19 #LargestVaccineDrive pic.twitter.com/syv5T8eHuR
— ICMR (@ICMRDELHI) April 21, 2021
“ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well,” the ICMR tweeted.
ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant).
ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant, the apex health research body said.
ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries, the ICMR stated.
“Covaxin has been found to effectively neutralise the double mutant strain as well,” it said.
Serum’s Covishield at ₹400 a dose for states, 600 for private hospitals
Covishield will be sold at ₹ 400 a shot to states and ₹ 600 to private hospitals, the Serum Institute of India (SII) said today, days ahead of a new round of vaccinations from May 1 that will include all above 18.
IMPORTANT ANNOUNCEMENT pic.twitter.com/bTsMs8AKth
— SerumInstituteIndia (@SerumInstIndia) April 21, 2021